

CRG-02: An AAV-based anti-VEGF gene therapy for angiogenic ocular conditions delivered via intravitreal injection



OPHTHALMOLOGY	Non-Clinical
Product Type	Recombinant Adeno-Associated Virus (rAAV)
Indication	Neovascular Age-related Macular Degeneration and Diabetic Retinopathy
Target	VEGF-A, VEGF-B and PlGF
MoA (Mechanism of Action)	CRG-02 (AAV2-sVEGFRv-1) is a recombinant adeno-associated virus serotype 2 encoding a truncated version of the naturally-occurring, alternatively-spliced soluble form of human VEGF receptor 1 (VEGFR1). This variant has been shown to have an anti-angiogenic therapeutic effect by exerting its anti-VEGF activity through the potential binding of VEGF-A, VEGF-B, and PlGF.
Competitiveness	Best in Class The proposed clinical dose of CRG-02 is 100-fold lower than similar anti-VEGF gene therapeutics currently under development by competitors.
Development Stage	Non-Clinical
Route of Administration	Intravitreal injection